

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM326521

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Trademark Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PDL BioPharma, Inc.		12/16/2014	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Vicuron Pharmaceuticals Inc.		
Street Address:	200 South Wacker Drive		
Internal Address:	Suite 2550		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60606		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	3522268	EXULET	
Serial Number:	85140086	EXULETT	
Registration Number:	3522528	DALBAK	
Registration Number:	3541877	ZEVEN	
CORRESPONDENCE DATA			
Fax Number:	6175265000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	617-526-6448		
Email:	huelinh.tran@wilmerhale.com		
Correspondent Name:	Michael J. Bevilacqua, Esq.		
Address Line 1:	Wilmer Cutler Pickering Hale and DorrLLP		
Address Line 2:	60 State Street		
Address Line 4:	Boston, MASSACHUSETTS 02109		
ATTORNEY DOCKET NUMBER:	2205.364.129		
NAME OF SUBMITTER:	Michael J. Bevilacqua		
SIGNATURE:	/michael j. bevilacqua/		
DATE SIGNED:	12/18/2014		
Total Attachments: 2			

OP \$115.00 3522268

source=release trademark security agreement pdl biopharma to vicuron pharmaceuticals#page1.tif

source=release trademark security agreement pdl biopharma to vicuron pharmaceuticals#page2.tif

RELEASE OF TRADEMARK SECURITY AGREEMENT

WHEREAS, Vicuron Pharmaceuticals Inc., a Delaware corporation (the "Grantor"), entered into that certain Trademark Security Agreement (the "Agreement"), dated as of October 31, 2013, which was recorded in the United States Patent and Trademark Office on October 31, 2013 at Reel 5143 and Frame 0258, that by its terms granted to PDL BioPharma, Inc., a Delaware corporation (the "Lender"), a security interest and continuing lien in the Trademark Collateral (as defined in the Agreement) in favor of the Lender; and

WHEREAS, the Lender has agreed to terminate and release the entirety of its security interest in the Trademark Collateral;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, effective as of even date herewith, the Lender hereby irrevocably (a) releases, relinquishes, terminates and discharges its security interest in the Trademark Collateral, including the registrations and applications listed on Exhibit A hereto, and (b) reassigns any and all such right, title and interest (if any) that the Lender may have in the Trademark Collateral to the Grantor, and any right, title or interest of the Lender in such Trademark Collateral shall hereby immediately cease and become void. The Lender further agrees, for itself, its successors and assigns, to execute such further documents and to perform such further lawful acts as may reasonably be requested by the Grantor, to effectuate this release.

The Lender acknowledges that it is the purpose of this document to memorialize the aforementioned release of its security interest in the Trademark Collateral in a form suitable for recordation in the United States Patent and Trademark Office and hereby consents to the recording of this document in the United States Patent and Trademark Office.

IN WITNESS WHEREOF the Lender by the signature below of its duly authorized representative agrees to be bound by the provisions of this release agreement as of the date of execution, this 16 day of December, 2014.

PDL BIOPHARMA, INC.



Name: Christopher Stone
Title: VP and General Counsel

Exhibit A

TRADEMARK SECURITY INTEREST RELEASE

<u>Trademark</u>	<u>Application/Registration Number</u>	<u>Filing/Registration Date</u>
EXULET	3,522,268	10/21/2008
EXULETT	85/140,086	09/28/2010
DALBAK	3,522,528	10/21/2008
ZEVEN	3,541,877	12/02/2008